ATE311196T1 - Zusammensetzungen geeignet zur kontrollierten freisetzung des hormons gnrh und dessen analoga - Google Patents

Zusammensetzungen geeignet zur kontrollierten freisetzung des hormons gnrh und dessen analoga

Info

Publication number
ATE311196T1
ATE311196T1 AT98923763T AT98923763T ATE311196T1 AT E311196 T1 ATE311196 T1 AT E311196T1 AT 98923763 T AT98923763 T AT 98923763T AT 98923763 T AT98923763 T AT 98923763T AT E311196 T1 ATE311196 T1 AT E311196T1
Authority
AT
Austria
Prior art keywords
controlled release
analogues
gnrh
compositions suitable
hormone gnrh
Prior art date
Application number
AT98923763T
Other languages
English (en)
Inventor
Patrick J Burns
John W Gibson
Arthur J Tipton
Original Assignee
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26668592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE311196(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Durect Corp filed Critical Durect Corp
Application granted granted Critical
Publication of ATE311196T1 publication Critical patent/ATE311196T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
AT98923763T 1997-05-28 1998-05-26 Zusammensetzungen geeignet zur kontrollierten freisetzung des hormons gnrh und dessen analoga ATE311196T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4778997P 1997-05-28 1997-05-28
US09/001,123 US6051558A (en) 1997-05-28 1997-12-30 Compositions suitable for controlled release of the hormone GnRH and its analogs
PCT/US1998/010668 WO1998053837A1 (en) 1997-05-28 1998-05-26 COMPOSITIONS SUITABLE FOR CONTROLLED RELEASE OF THE HORMONE GnRH AND ITS ANALOGS

Publications (1)

Publication Number Publication Date
ATE311196T1 true ATE311196T1 (de) 2005-12-15

Family

ID=26668592

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98923763T ATE311196T1 (de) 1997-05-28 1998-05-26 Zusammensetzungen geeignet zur kontrollierten freisetzung des hormons gnrh und dessen analoga

Country Status (10)

Country Link
US (1) US6051558A (de)
EP (1) EP1017411B1 (de)
AT (1) ATE311196T1 (de)
AU (1) AU743086C (de)
BR (1) BR9809189A (de)
CA (1) CA2291087C (de)
DE (1) DE69832631T2 (de)
ES (1) ES2255162T3 (de)
NZ (1) NZ501219A (de)
WO (1) WO1998053837A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US20060025328A1 (en) * 1997-05-28 2006-02-02 Burns Patrick J Compositions suitable for controlled release of the hormone GnRH and its analogs
US6028057A (en) * 1998-02-19 2000-02-22 Thorn Bioscience, Llc Regulation of estrus and ovulation in gilts
AU5025300A (en) * 1999-06-18 2001-01-09 Southern Biosystems, Inc. Compositions for controlled release of the hormone gnrh and its analogs
US7074803B2 (en) * 2001-03-02 2006-07-11 Durect Corporation Opioid formulations
JP4361710B2 (ja) * 2000-04-19 2009-11-11 ジェネンテック・インコーポレーテッド 徐放製剤
CA2423431A1 (en) * 2000-10-06 2002-04-11 Durect Corporation Devices and methods for management of inflammation
JP2004512369A (ja) * 2000-10-30 2004-04-22 ユニバーシティ・オブ・チューリッヒ 尿失禁の治療のためのｇｎｒｈアナログ
EP1365770A2 (de) * 2001-02-07 2003-12-03 Durect Corporation Vorrichtungen und verfahren zur erhaltung der knochendichte
DK1397155T3 (en) * 2001-06-21 2015-12-07 Genentech Inc Prolonged release formulation
US7479535B2 (en) * 2002-02-25 2009-01-20 Guilford Pharmaceuticals, Inc. Phosphorous-containing compounds with polymeric chains, and methods of making and using the same
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
SI1575569T1 (sl) 2002-12-13 2010-12-31 Durect Corp Oralni sistem dostave zdravila, ki obsega visokoviskozne tekoče nosilne materiale
EP1684782B1 (de) 2003-10-03 2015-09-30 Thorn BioScience, LLC Verfahren zur synchronisierung der ovulation für zeitlich angepasstes brüten ohne hitzenachweis
EP2286791B1 (de) * 2003-12-30 2014-03-26 Durect Corporation Polymereimplantate, welche vorzugsweise ein Gemisch von PEG und PLG enthalten, für kontrollierte Freisetzung von Wirkstoffen
EP3103477A1 (de) * 2004-09-17 2016-12-14 Durect Corporation Anhaltende lokalanästhetikumzusammensetzung mit saib
CN101163464A (zh) * 2004-12-23 2008-04-16 杜雷科特公司 优选含有PEG和PLG混合物的控制释放GnRH的聚合物植入物
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20080286375A1 (en) * 2005-11-15 2008-11-20 Amorepacific Corporation Method for Preparing Sustained-Release Microparticles Comprising Sucrose Acetate Isobutyrate
NZ595633A (en) * 2005-12-02 2013-05-31 Parnell Lab Aust Pty Ltd Increasing pregnancy rates
US20070197435A1 (en) * 2006-02-17 2007-08-23 Webel Stephen K Process for the synchronization of ovulation for timed breeding without heat detection
KR100908517B1 (ko) * 2006-07-04 2009-07-20 (주)아모레퍼시픽 호흡기계 약제 전달을 위한 서방형 다공성 미세입자 및 그제조 방법
PL2117521T3 (pl) 2006-11-03 2012-11-30 Durect Corp Transdermalne systemy dostarczania zawierające bupiwakainę
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
US8058237B2 (en) 2007-08-07 2011-11-15 Advanced Technologies & Regenerative Medicine, LLC Stable composition of GDF-5 and method of storage
EP3326621A1 (de) * 2007-12-06 2018-05-30 Durect Corporation Orale arzneimitteldosierformen
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
EP2254559B1 (de) 2008-02-08 2018-10-10 Foresee Pharmaceuticals Co., Ltd. Zusammensetzung zur verzögerten freisetzung von proteinen oder peptiden
JP5737949B2 (ja) 2008-02-08 2015-06-17 キューピーエス リミテッド ライアビリティ カンパニー 薬物制御送達用の非ポリマー組成物
WO2009129101A1 (en) * 2008-04-14 2009-10-22 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered gdf-5 formulations
CA2726247C (en) 2008-05-29 2018-06-26 Isr Immune System Regulation Ab Method and means for treating viral disease, in particular hiv/aids
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
BR122013009981B1 (pt) 2009-04-23 2020-02-11 United-Ah Ii, Llc Composição para sincronizar o tempo de inseminação
AR082266A1 (es) 2011-05-13 2012-11-28 Univ Nac Del Litoral Microparticula inyectable de liberacion controlada
BR112015012453A8 (pt) 2012-11-28 2021-06-29 Jbs United Animal Health Ii Llc métodos e usos para sincronizar o tempo de ovulação e de inseminação em uma leitoa
US9572885B2 (en) 2013-03-15 2017-02-21 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
CN106456704A (zh) 2014-04-16 2017-02-22 Veyx-药物有限公司 兽药组合物和其应用
US20170106017A1 (en) * 2014-05-16 2017-04-20 Neuraltus Pharmaceuticals, Inc. Methods and compositions for treatment of macrophage-related disorders
CL2016000217A1 (es) * 2016-01-27 2016-07-01 Farmacologia En Aquacultura Veterinaria Fav S A Nueva composición veterinaria inyectable para la sincronización del desove en peces
SG11201811760VA (en) 2016-07-06 2019-01-30 Durect Corp Oral dosage form with drug composition, barrier layer and drug layer
CN111202837B (zh) * 2018-11-22 2022-02-08 中国农业大学 一种用于控制马属动物排卵的制剂及控制排卵的方法
EP4090353A4 (de) 2020-01-13 2023-08-09 Durect Corporation Arzneimittelabgabesysteme mit verzögerter freisetzung mit reduzierten verunreinigungen und verwandte verfahren
JP2024503402A (ja) 2021-01-12 2024-01-25 デュレクト コーポレーション 徐放性薬物送達システム及び関連の方法
CN113350275B (zh) * 2021-06-19 2022-09-06 江西农业大学 一种烯丙孕素缓释注射液及其制备方法和应用
WO2023027950A1 (en) 2021-08-25 2023-03-02 Reprologix Methods for reproductive management of sheep and goats

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
NO139560C (no) * 1972-04-29 1979-04-04 Takeda Chemical Industries Ltd Analogifremgangsmaate til fremstilling av terapeutisk virksomme nonapeptidamid-derivater
DK568274A (de) * 1973-11-01 1975-06-23 Wellcome Found
DE2438350C3 (de) * 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
GB1524747A (en) * 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US5350741A (en) * 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
JP3219096B2 (ja) * 1990-05-10 2001-10-15 ニコメド ファーマ エイエス ｎ―グリコフロール類及びｎ―エチレングリコール類を含有する医薬製剤
IT1240643B (it) * 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
NZ240214A (en) * 1990-10-16 1993-02-25 Takeda Chemical Industries Ltd Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5487898A (en) * 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
YU87892A (sh) * 1991-10-01 1995-12-04 Eli Lilly And Company Lilly Corporate Center Injektibilne formulacije produženog otpuštanja i postupci za njihovo dobijanje i primenu
ES2136624T3 (es) * 1991-10-21 1999-12-01 Peptech Limited Implante biocompatible para regular la ovulacion en yeguas.
JPH07112940A (ja) * 1993-08-26 1995-05-02 Takeda Chem Ind Ltd 徐放性非経口投与製剤およびその製造方法
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
WO1996039995A1 (en) * 1995-06-07 1996-12-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system

Also Published As

Publication number Publication date
CA2291087C (en) 2009-12-29
ES2255162T3 (es) 2006-06-16
EP1017411A1 (de) 2000-07-12
US6051558A (en) 2000-04-18
AU743086B2 (en) 2002-01-17
NZ501219A (en) 2002-03-01
DE69832631T2 (de) 2006-08-10
BR9809189A (pt) 2002-12-03
CA2291087A1 (en) 1998-12-03
DE69832631D1 (de) 2006-01-05
AU7598098A (en) 1998-12-30
EP1017411A4 (de) 2002-09-04
AU743086C (en) 2004-07-15
WO1998053837A1 (en) 1998-12-03
EP1017411B1 (de) 2005-11-30

Similar Documents

Publication Publication Date Title
ATE311196T1 (de) Zusammensetzungen geeignet zur kontrollierten freisetzung des hormons gnrh und dessen analoga
DK1006935T3 (da) Styret afgivelsessystem med en væske med höj viskositet
DK1274459T3 (da) Præparater med vedholdende frigivelse indeholdende væksthormon
IL112112A (en) Peptides with growth hormone releasing properties and pharmaceutical compositions containing them
IL117144A0 (en) Pharmaceutical compositions containing nucleic acids
MX9703550A (es) Secretagogos de hormona del crecimiento, peptidomimeticos, de bajo peso molecular.
HU900108D0 (en) Composition of controlled active ingredient delivery, operating by hydrogel
NZ311208A (en) Composition comprising an active agent dissolved in a glass-forming carrier comprising a glass-forming substance containing a plasticizer, composition is liquid or jelly-like below 50 degrees
UA27143C2 (uk) Рідка фармацевтичhа композиція в формі аерозолю
BR9812313A (pt) Sistema de liberação controlada de lìquido de viscosidade elevada como um dispositivo
OA09772A (en) "mometasone furoate monohydrate, process for making same and pharmaceutical compositions".
EP0398619A3 (de) Stabilisierte, den epidermalen Wachstumsfaktor enthaltende Mittel
MY101919A (en) Pharmaceutical compositions
NZ225329A (en) Agent for enhancing compatability of two components in a mixture
CA2270177A1 (en) Transdermal administration of ment
MX9300586A (es) Nuevos fragmentos de hormona paratiroidea proceso para su preparacion y composiciones farmaceuticas que los contienen.
BR9307687A (pt) Análogos de insulina
SE9403389D0 (sv) Pharmaceutical composition containing derivattves of sex hormones
AU7723700A (en) Non-mammalian gnrh analogs and uses thereof in regulation of fertility and pregnancy
BG105303A (en) Pharmaceutical compositions comprising ibuprofen and domperidone
ZA87332B (en) Compositions containing fixed combinations
EP1074264A4 (de) Inhibitoren für die gefässneubildung
ES2106852T3 (es) Composicion oftalmica que contiene hemihidrato de timolol.
NZ320211A (en) Lipid alcohols as new immunosuppressive and antiviral drugs
DK0911038T3 (da) Vandfri sammensætning omfattende lactulose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties